Videos de Experimentos Relacionados
La expresión de CD38 / CD8 y la insuficiencia de HAART.
Lancet (London, England)
|August 25, 1999
Resumen
No abstract available in PubMed .
Videos de Conceptos Relacionados
También podría leer
Artículos Relacionados
Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.
Ordenar por
Same author
Lung ultrasound for the diagnosis and monitoring of community-acquired pneumonia in children: a prospective observational study.
Frontiers in pediatrics·2026
Same author
SGLT2i Dapagliflozin in primary prevention of chemotherapy induced cardiotoxicity in breast cancer patients treated with neo-adjuvant anthracycline-based chemotherapy +/- trastuzumab: rationale and design of the multicenter PROTECT trial.
Cardio-oncology (London, England)·2025
Same author
Bioimpedance-derived body composition parameters predict mortality and dose-limiting toxicity: the multicenter ONCO-BIVA study.
ESMO open·2024
Same author
A 1-year follow-up study on checkpoint inhibitor-induced colitis: results from a European consortium.
ESMO open·2024
Same author
Six-month humoral and cellular immune response to the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors: a longitudinal cohort study with a focus on the variants of concern.
ESMO open·2022
Same author
Humoral and cellular response before and after the fourth BNT162b2 vaccine dose in patients with solid tumors on active treatment.
Annals of oncology : official journal of the European Society for Medical Oncology·2022
Same journal
Assisted dying and the silencing of medicine's next generation.
Lancet (London, England)·2026
Same journal
Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.
Lancet (London, England)·2026
Same journal
Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.
Lancet (London, England)·2026
Same journal
[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.
Lancet (London, England)·2026
Same journal
Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.
Lancet (London, England)·2026